Literature DB >> 31727227

The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia.

Pascal Sienaert1, Peter van Harten2, Didi Rhebergen3.   

Abstract

Although highly prevalent, motor syndromes in psychiatry and motor side effects of psychopharmacologic agents remain understudied. Catatonia is a syndrome with specific motor abnormalities that can be seen in the context of a variety of psychiatric and somatic conditions. The neuroleptic malignant syndrome is a lethal variant, induced by antipsychotic drugs. Therefore, antipsychotics should be used with caution in the presence of catatonic signs. Antipsychotics and other dopamine-antagonist drugs can also cause motor side effects such as akathisia, (tardive) dyskinesia, and dystonia. These syndromes share a debilitating impact on the functioning and well-being of patients. To reduce the risk of inducing these side effects, a balanced and well-advised prescription of antipsychotics is of utmost importance. Clinicians should be able to recognize motor side effects and be knowledgeable of the different treatment modalities.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Akathisia; Catatonia; Dystonia; Malignant neuroleptic syndrome; Tardive dyskinesia

Mesh:

Substances:

Year:  2019        PMID: 31727227     DOI: 10.1016/B978-0-444-64012-3.00025-3

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  4 in total

1.  Brief psychotic disorder revealing a SARS-COV-2 encephalopathy in a patient with myasthenia gravis: A case report.

Authors:  F Berthet; D-A Niculcea; N Younes; E Brunet-Gouet
Journal:  Encephale       Date:  2022-05-19       Impact factor: 2.787

Review 2.  Catatonia in autism spectrum disorders: A systematic review and meta-analysis.

Authors:  J Vaquerizo-Serrano; G Salazar De Pablo; J Singh; P Santosh
Journal:  Eur Psychiatry       Date:  2021-12-15       Impact factor: 5.361

3.  Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia.

Authors:  Olga Yu Fedorenko; Diana Z Paderina; Elena G Kornetova; Evgeniya G Poltavskaya; Ivan V Pozhidaev; Anastasiia A Goncharova; Maxim B Freidin; Anna V Bocharova; Nikolay A Bokhan; Anton J M Loonen; Svetlana A Ivanova
Journal:  Diagnostics (Basel)       Date:  2022-06-22

Review 4.  Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence.

Authors:  Daniel Felipe Ariza-Salamanca; María Gabriela Corrales-Hernández; María José Pachón-Londoño; Isabella Hernández-Duarte
Journal:  Front Mol Neurosci       Date:  2022-09-29       Impact factor: 6.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.